MX2022013096A - Formulacion aerosolizable. - Google Patents

Formulacion aerosolizable.

Info

Publication number
MX2022013096A
MX2022013096A MX2022013096A MX2022013096A MX2022013096A MX 2022013096 A MX2022013096 A MX 2022013096A MX 2022013096 A MX2022013096 A MX 2022013096A MX 2022013096 A MX2022013096 A MX 2022013096A MX 2022013096 A MX2022013096 A MX 2022013096A
Authority
MX
Mexico
Prior art keywords
aerosolisable formulation
nicotine
aerosolisable
formulation
aerosol
Prior art date
Application number
MX2022013096A
Other languages
English (en)
Inventor
Connor Bruton
Anna Azzopardi
Pena Maria Montserrat Sanchez
Andrew Burton
George Mclachlan
Olatunde Akande
Victoria Mckeown
Jay Morris
Paulo Aguiar
Peter Clayton
Original Assignee
Nicoventures Trading Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicoventures Trading Ltd filed Critical Nicoventures Trading Ltd
Publication of MX2022013096A publication Critical patent/MX2022013096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En un aspecto, se proporciona una formulación aerosolizable que comprende: (i) uno o más agentes formadores de aerosol y (ii) nicotina; en donde la nicotina comprende (R)-nicotina en una cantidad de entre aproximadamente 1% a aproximadamente 4.5% en peso de la nicotina total.
MX2022013096A 2020-04-24 2021-04-23 Formulacion aerosolizable. MX2022013096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006008.3A GB202006008D0 (en) 2020-04-24 2020-04-24 Aerosolisable formulation
PCT/GB2021/050997 WO2021214491A1 (en) 2020-04-24 2021-04-23 Aerosolisable formulation

Publications (1)

Publication Number Publication Date
MX2022013096A true MX2022013096A (es) 2022-12-08

Family

ID=71080277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013096A MX2022013096A (es) 2020-04-24 2021-04-23 Formulacion aerosolizable.

Country Status (6)

Country Link
US (1) US20230144701A1 (es)
EP (1) EP4138585B1 (es)
CA (1) CA3172538A1 (es)
GB (1) GB202006008D0 (es)
MX (1) MX2022013096A (es)
WO (1) WO2021214491A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112182A1 (en) * 2015-10-23 2017-04-27 Next Generation Labs, LLC Nicotine composition for vaping devices and vaping devices employing the same
CN108697152B (zh) 2015-12-30 2022-01-11 下一代实验室有限责任公司 包含合成尼古丁的尼古丁替代疗法产品
KR20180111799A (ko) * 2016-02-01 2018-10-11 필립모리스 프로덕츠 에스.에이. 다수의 전력 공급부를 갖는 에어로졸 발생 장치
CN106770809B (zh) * 2017-03-15 2019-10-11 上海烟草集团有限责任公司 一种电子烟烟液中烟碱手性异构体的分析方法
EP3780976A4 (en) * 2018-04-17 2022-06-01 Poviva Corp. LIPOPHILIC, INGREDIENT COMPOSITIONS WITH REDUCED FOOD INFLUENCE

Also Published As

Publication number Publication date
WO2021214491A1 (en) 2021-10-28
EP4138585B1 (en) 2024-02-21
EP4138585A1 (en) 2023-03-01
CA3172538A1 (en) 2021-10-28
US20230144701A1 (en) 2023-05-11
GB202006008D0 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
UY29246A1 (es) Nuevos compuestos
RS52155B (en) PYROLO (3,4-c) PIRAZOL DERIVATIVE ACTIVE AS KINASE INHIBITORS
PL1933809T3 (pl) Kompozycje do dostarczania donosowego
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
ME00275B (me) ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
MEP36908A (en) omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
TW200510328A (en) 5-membered heterocycle-based p38 kinase inhibitors
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
MY163503A (en) Aerosol formulations for the inhalation of beta agonists
MY163126A (en) 1,2,3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2020005621A (es) Derivados de acidos grasos para tratar la esteatohepatitis no alcoholica.
NO20090407L (no) Aerosolformulering for inhalering av beta agonister
MX2022006736A (es) Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
MX2021005165A (es) Formulacion aerosolizable.
CR20220308A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2023005696A (es) Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.
TW200735864A (en) Immediate release pharmaceutical formulation
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
TW200626562A (en) Crystalline forms of 3-[5-chloro-4-[(2, 4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
DE50109650D1 (de) Topische behandlung bei der mastalgie
DK1684719T3 (da) Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger
MX2021005163A (es) Formulacion aerosolizable.
MX2022013096A (es) Formulacion aerosolizable.